Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot Applicable A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Transcatheter Tricuspid Valve Clipping Systems in Patients With Severe or Greater Tricuspid Regurgitation.
The transcatheter tricuspid valve clipping system is specially designed for the treatment of tricuspid regurgitation. Under the guidance of ultrasound and DSA imaging, the investigational device is advanced into the right ventricle via a femoral or jugular venous puncture approach. The clipping component grasps the edges of the dysfunctional valve leaflets (usually unable to close properly), thereby reducing the area of the tricuspid orifice that fails to coapt normally, achieving minimally invasive treatment of tricuspid regurgitation.
/ Not yet recruitingPhase 3IIT Prospective, multicenter, randomized controlled, superior efficacy study to evaluate the efficacy and safety of transcatheter mitral valve clip and controllable catheters for the treatment of functional mitral regurgitation disease
/ Not yet recruitingNot Applicable A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Safety of the Transcatheter Tricuspid Valvuloplasty System in Patients With Severe or Above Tricuspid Regurgitation
To evaluate the efficacy and safety of the transcatheter tricuspid valve ring system produced by Shanghai Huihe Medical Technology Co., Ltd. in the treatment of patients with severe or above tricuspid regurgitation who cannot be evaluated by clinicians for surgery.
100 Clinical Results associated with Shanghai Huihe Medical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Huihe Medical Technology Co., Ltd.
100 Deals associated with Shanghai Huihe Medical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Huihe Medical Technology Co., Ltd.